TISIDB

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Lateral cell membrane Cell junction, tight junction Membrane Multi-pass membrane protein Cell membrane, sarcolemma Membrane, caveola Note=Colocalizes with VAMP3 at the cell-cell contact in cardiac and skeletal muscle (By similarity). Its movement from the cytoplasm to membrane is an early event occurring concurrently with cell-cell contact. Colocalizes in epithelial cells with OCLN and TJP1 in an apical-lateral position within the z axis. Detected at cell-cell contact but never observed at the free surface of epithelial cells.
Domain	PF04831 Popeye protein conserved region
Function	Cell adhesion molecule involved in the establishment and/or maintenance of cell integrity. Involved in the formation and regulation of the tight junction (TJ) paracellular permeability barrier in epithelial cells (PubMed:16188940). Plays a role in VAMP3-mediated vesicular transport and recycling of different receptor molecules through its interaction with VAMP3. Plays a role in the regulation of cell shape and movement by modulating the Rho-family GTPase activity through its interaction with ARHGEF25/GEFT. Induces primordial adhesive contact and aggregation of epithelial cells in a Ca(2+)-independent manner. Also involved in striated muscle regeneration and repair and in the regulation of cell spreading (By similarity). Important for the maintenance of cardiac function. Plays a regulatory function in heart rate dynamics mediated, at least in part, through cAMP-binding and, probably, by increasing cell surface expression of the potassium channel KCNK2 and enhancing current density (PubMed:26642364). Is also a caveolae-associated protein important for the preservation of caveolae structural and functional integrity as well as for heart protection against ischemia injury.

> Gene Ontology [ TOP ]
Biological Process	GO:0001881 receptor recycling GO:0001919 regulation of receptor recycling GO:0001921 positive regulation of receptor recycling GO:0002027 regulation of heart rate GO:0002244 hematopoietic progenitor cell differentiation GO:0002931 response to ischemia GO:0003013 circulatory system process GO:0003015 heart process GO:0003161 cardiac conduction system development GO:0003163 sinoatrial node development GO:0007034 vacuolar transport GO:0007507 heart development GO:0007517 muscle organ development GO:0007519 skeletal muscle tissue development GO:0008015 blood circulation GO:0008016 regulation of heart contraction GO:0008360 regulation of cell shape GO:0014706 striated muscle tissue development GO:0016197 endosomal transport GO:0022406 membrane docking GO:0022604 regulation of cell morphogenesis GO:0031589 cell-substrate adhesion GO:0032456 endocytic recycling GO:0034446 substrate adhesion-dependent cell spreading GO:0035051 cardiocyte differentiation GO:0040017 positive regulation of locomotion GO:0042391 regulation of membrane potential GO:0042692 muscle cell differentiation GO:0043112 receptor metabolic process GO:0044057 regulation of system process GO:0048278 vesicle docking GO:0048738 cardiac muscle tissue development GO:0051146 striated muscle cell differentiation GO:0055001 muscle cell development GO:0055002 striated muscle cell development GO:0055006 cardiac cell development GO:0055007 cardiac muscle cell differentiation GO:0055013 cardiac muscle cell development GO:0060047 heart contraction GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0060627 regulation of vesicle-mediated transport GO:0060920 cardiac pacemaker cell differentiation GO:0060921 sinoatrial node cell differentiation GO:0060926 cardiac pacemaker cell development GO:0060931 sinoatrial node cell development GO:0060973 cell migration involved in heart development GO:0090136 epithelial cell-cell adhesion GO:1903335 regulation of vacuolar transport GO:1903522 regulation of blood circulation GO:2001135 regulation of endocytic recycling
Molecular Function	GO:0030551 cyclic nucleotide binding GO:0030552 cAMP binding
Cellular Component	GO:0005901 caveola GO:0005923 bicellular tight junction GO:0016328 lateral plasma membrane GO:0031253 cell projection membrane GO:0042383 sarcolemma GO:0043296 apical junction complex GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0070160 occluding junction GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04530 Tight junction
Reactome	-

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between BVES and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of BVES in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of BVES in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.128	0.78
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.064	0.943
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.169	0.806
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.404	0.212
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.753	0.502
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.037	0.978
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.282	0.533
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.076	0.943
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.789	0.456
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.382	0.479
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.22	0.0716
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.194	0.297

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of BVES in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BVES. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BVES. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BVES. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BVES. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of BVES expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between BVES and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	BVES
Name	blood vessel epicardial substance
Aliases	HBVES; POPDC1; popeye domain containing 1; popeye domain-containing protein 1; popeye protein 1
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting BVES collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse BVES